Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The conformation of this loop is virtually identical in the three HDLP structures (Finnin et al., 1999), suggesting that the surface of HDLP is less malleable than that of HDAC8 around the binding site pocket.”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“The apparent reduced flexibility in the HDLP surface may also explain why it is less efficient in histone deacetylase assays (Finnin et al., 1999).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“Finnin et al. (1999) have suggested that H143 protonates the lysine after the carbon-nitrogen scissile bond breaks.”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Finnin et al., 1999
In the citing paper
“HDAC6 also contributes to mitochondrial trafficking and misfolded protein clearance (Perry et al., 2017; Finnin et al., 1999), highlighting the HDAC6–microtubule–mitochondria axis as an important regulatory node beyond chromatin-dependent mechanisms.”
From Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook (2026) · cites this paper as Finnin et al., 1999
In the citing paper
“HDAC6 also contributes to mitochondrial trafficking and misfolded protein clearance (Perry et al., 2017; Finnin et al., 1999), highlighting the HDAC6–microtubule–mitochondria axis as an important regulatory node beyond chromatin-dependent mechanisms.”
From Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook (2026) · cites this paper as Finnin et al., 1999
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures
Kraulis, P. J. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891004399 · Cited by 14,085
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
[26] Raster3D: Photorealistic molecular graphics
Merritt, E. A., & Bacon, D. J. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)77028-9 · Cited by 3,739
The relation between the divergence of sequence and structure in proteins.
Chothia, C., & Lesk, A. M. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04288.x · Cited by 2,458
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815
The complete genome of the hyperthermophilic bacterium Aquifex aeolicus
Deckert, G., Warren, P. V., Gaasterland, T., Young, W. G., Lenox, A. L., Graham, D. E., Overbeek, R., Snead, M. A., Keller, M., Aujay, M., et al. (1998) · Nature · doi:10.1038/32831 · Cited by 1,097
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citation
Research works printed but not linked: 2
- Cohen,L. A. et al. Inhibition of N-methylnitrosourea-induced tumours by the cytodifferentiating agent, suberanilohydroxamic acid (SAHA). Proc. AACR 39, 108, abstr. 736 (1998).
- Desai,D., El-Bayoumy,K. & Amin,S. Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylinitros-amino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Proc. AACR 40, 2396, abstr. 362 (1999).
Cited by
Items 401–500 of 1,007
Ye, R., Ke, Z., Tan, C., He, L., Ji, L., & Mao, Z. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201300814 · Cited by 87
Gu, W., Cueto, M., Jensen, P. R., Fenical, W., & Silverman, R. B. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.04.025 · Cited by 87
Epigenetic mechanisms regulate stage differentiation in the minimized protozoan Giardia lamblia
Sonda, S., Morf, L., Bottová, I., Baetschmann, H., Rehrauer, H., Caflisch, A., Hakimi, M., & Hehl, A. B. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07062.x · Cited by 87
New agents in cancer clinical trials
Adams, J., & Elliott, P. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204088 · Cited by 87
Daud, A. I., Dawson, J., DeConti, R. C., Bicaku, E., Marchion, D., Bastien, S., Hausheer, F. A., Lush, R., Neuger, A., Sullivan, D. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1931 · Cited by 86
Activation and Inhibition of Histone Deacetylase 8 by Monovalent Cations
Gantt, S. L., Joseph, C. G., & Fierke, C. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033399 · Cited by 86
Organ-specific requirements for Hdac1 in liver and pancreas formation
Noël, E. S., Casal, A., Busch‐Nentwich, E. M., Verkade, H. M., Dong, P. D. S., Stemple, D. L., & Ober, E. A. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.06.040 · Cited by 86
Histone Modification Therapy of Cancer
Biancotto, C., Frigè, G., & Minucci, S. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60013-7 · Cited by 86
The use of diversity profiling to characterize chemical modulators of the histone deacetylases
Blackwell, L. J., Norris, J. L., Suto, C. M., & Janzen, W. P. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.03.004 · Cited by 86
Bouchain, G., Leit, S. M., Fréchette, S., Khalil, E. A., Lavoie, R., Moradei, O. M., Woo, S. H., Fournel, M., Yan, P. T., Kalita, A., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020377a · Cited by 86
Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900850t · Cited by 84
Grassi, G. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg118 · Cited by 84
Neureiter, D., Zopf, S., Leu, T., Dietze, O., Hauser‐Kronberger, C., Hahn, E. G., Herold, C., & Ocker, M. (2007) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520600874198 · Cited by 84
Molecular Basis of Neurotrophin−Receptor Interactions
Pattarawarapan, M., & Burgess, K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030221q · Cited by 83
Zeng, X., Yin, B., Hu, Z., Liao, C., Liu, J., Li, S., Li, Z., Nicklaus, M. C., Zhou, G., & Jiang, S. (2010) · Organic Letters · doi:10.1021/ol100308a · Cited by 83
Newkirk, T. L., Bowers, A. A., & Williams, R. M. (2009) · Natural Product Reports · doi:10.1039/b817886k · Cited by 83
Peng, F.-W., Ji, X., Wu, T.-T., Xue, J., Ren, Z., Liu, D., Wang, X., Chen, X.-H., Zhang, J., Xu, Y., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.033 · Cited by 83
Epigenetic inhibitors target multiple stages of Plasmodium falciparum parasites
Coetzee, N., von Grüning, H., Opperman, D., van der Watt, M., Reader, J., & Birkholtz, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-59298-4 · Cited by 83
Strait, K. A., Dabbas, B., Hammond, E. H., Warnick, C. T., Iistrup, S. J., & Ford, C. D. (2002) · PubMed · Cited by 83
Histone deacetylase modulators provided by Mother Nature
Seidel, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2012) · Genes & Nutrition · doi:10.1007/s12263-012-0283-9 · Cited by 82
On the inhibition of histone deacetylase 8
Estiu, G., West, N., Mazitschek, R., Greenberg, E., Bradner, J. E., & Wiest, O. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.080 · Cited by 82
Marwick, J. A., Ito, K., Adcock, I. M., & Kirkham, P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.6.745 · Cited by 82
Montero, A., Beierle, J. M., Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809508f · Cited by 81
Structural basis for the design and synthesis of selective HDAC inhibitors
Micco, S. D., Chini, M. G., Terracciano, S., Bruno, I., Riccio, R., & Bifulco, G. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.036 · Cited by 81
Dowling, D. P., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2010) · Biochemistry · doi:10.1021/bi1005046 · Cited by 81
Guide to the draft human genome
Wolfsberg, T. G., McEntyre, J., & Schuler, G. D. (2001) · Nature · doi:10.1038/35057000 · Cited by 81
Curcio, A., Rocca, R., Alcaro, S., & Artese, A. (2024) · Pharmaceuticals · doi:10.3390/ph17050620 · Cited by 81
Computer-Aided Drug Design in Epigenetics
Lu, W., Zhang, R., Jiang, H., Zhang, H., & Luo, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00057 · Cited by 81
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities
Konstantinopoulos, P. A., Vandoros, G. P., & Papavassiliou, A. G. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0182-5 · Cited by 81
Asou, N. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00003-3 · Cited by 80
Schäfer, S., Saunders, L. R., Eliseeva, E. D., Velena, A., Jung, M., Schwienhorst, A., Strasser, A., Dickmanns, A., Ficner, R., Schlimme, S., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.092 · Cited by 80
HDAC8 substrates: Histones and beyond
Wolfson, N. A., Pitcairn, C. A., & Fierke, C. A. (2013) · Biopolymers · doi:10.1002/bip.22135 · Cited by 80
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y., & He, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190122144949 · Cited by 80
HDAC Inhibition and Graft Versus Host Disease
Choi, S. W., & Reddy, P. R. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00007 · Cited by 80
Emerging trends in metalloprotein inhibition
Rouffet, M., & Cohen, S. M. (2011) · Dalton Transactions · doi:10.1039/c0dt01743d · Cited by 79
Structure-based design of molecular cancer therapeutics
van Montfort, R. L. M., & Workman, P. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.02.003 · Cited by 79
Thioredoxin in cancer—Role of histone deacetylase inhibitors
Marks, P. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.09.005 · Cited by 79
Self-citationIngram, A. K., & Horn, D. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03018.x · Cited by 79
Trans-regulation of Histone Deacetylase Activities through Acetylation
Luo, Y., Jian, W., Stavreva, D., Fu, X., Hager, G., Bungert, J., Huang, S., & Qiu, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.038356 · Cited by 78
Woo, S. H., Fréchette, S., Khalil, E. A., Bouchain, G., Vaisburg, A., Bernstein, N., Moradei, O. M., Leit, S. M., Allan, M., Fournel, M., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020154k · Cited by 78
Recent advances in class IIa histone deacetylases research
Asfaha, Y., Schrenk, C., Avelar, L. A. A., Hamacher, A., Pflieger, M., Kassack, M. U., & Kurz, T. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115087 · Cited by 78
Metabolism as a key to histone deacetylase inhibition
Rajendran, P., Williams, D. E., Ho, E., & Dashwood, R. H. (2011) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2011.557713 · Cited by 78
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Lodewijk, I., Nunes, S. P., Henrique, R., Jerónimo, C., Dueñas, M., & Paramio, J. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01046-0 · Cited by 78
Histone deacetylation inhibits IL4 gene expression in T cells
Valapour, M., Guo, J., Schroeder, J. T., Keen, J. C., Cianferoni, A., Casolaro, V., & Georas, S. N. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121145 · Cited by 78
New anti-cancer strategies: Epigenetic therapies and biomarkers
Balch, C. (2005) · Frontiers in bioscience · doi:10.2741/1668 · Cited by 78
Wang, M., Gao, Y., Qu, P., Qing, S., Qiao, F., Zhang, Y., Mager, J., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13899-8 · Cited by 78
Functional Requirement for Histone Deacetylase 1 in Caenorhabditis elegans Gonadogenesis
Dufourcq, P., Victor, M., Gay, F., Calvo, D., Hodgkin, J., & Shi, Y. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.9.3024-3034.2002 · Cited by 78
Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin
Wong, P. G., Glozak, M. A., Cao, T. V., Vaziri, C., Seto, E., & Alexandrow, M. G. (2010) · Cell Cycle · doi:10.4161/cc.9.21.13596 · Cited by 77
Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases
Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R., et al. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.01.030 · Cited by 77
Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors
Suzuki, N., Suzuki, T., Ota, Y., Nakano, T., Kurihara, M., Okuda, H., Yamori, T., Tsumoto, H., Nakagawa, H., & Miyata, N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900125m · Cited by 77
Massa, S., Mai, A., Sbardella, G., Esposito, M., Ragno, R., Loidl, P., & Brosch, G. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015515v · Cited by 77
Wójcikowska, B., Botor, M., Morończyk, J., Wójcik, A. M., Nodzyński, T., Karcz, J., & Gaj, M. D. (2018) · Frontiers in Plant Science · doi:10.3389/fpls.2018.01353 · Cited by 77
Ruefli, A. A., Bernhard, D., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2002) · International Journal of Cancer · doi:10.1002/ijc.10327 · Cited by 76
Expression, purification, assay, and crystal structure of perdeuterated human arginase I
Costanzo, L. D., Moulin, M., Haertlein, M., Meilleur, F., & Christianson, D. W. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.04.036 · Cited by 76
Schneider, B. J., Kalemkerian, G. P., Bradley, D., Smith, D. C., Egorin, M. J., Daignault, S. D., Dunn, R. L., & Hussain, M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9503-6 · Cited by 76
Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors
He, S., Dong, G., Wang, Z., Chen, W., Huang, Y., Li, Z., Jiang, Y., Liu, N., Yao, J., Miao, Z., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500327q · Cited by 76
Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Oehme, I., Deubzer, H. E., Lodrini, M., Milde, T., & Witt, O. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241658 · Cited by 75
SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins
Binda, O., Nassif, C., & Branton, P. E. (2008) · Oncogene · doi:10.1038/sj.onc.1211014 · Cited by 75
McCarthy, A. A., Peterson, N. A., Knijff, R., & Baker, E. N. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.11.034 · Cited by 74
Activity-Guided Design of HDAC11-Specific Inhibitors
Son, S. I., Cao, J., Zhu, C.-L., Miller, S. P., & Lin, H. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00292 · Cited by 74
Chen, J.-B., Chern, T.-R., Wei, T.-T., Chen, C.-C., Lin, J.-H., & Fang, J.-M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400179b · Cited by 74
Snykers, S., Henkens, T., De Rop, E., Vinken, M., Fraczek, J., De Kock, J., De Prins, E., Geerts, A., Rogiers, V., & Vanhaecke, T. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.009 · Cited by 74
Evolution of the arginase fold and functional diversity
Dowling, D. P., Di Costanzo, L., Gennadios, H. A., & Christianson, D. W. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7554-z · Cited by 74
Targeting class I histone deacetylases in cancer therapy
Delcuve, G. P., Khan, D. H., & Davie, J. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.729042 · Cited by 74
Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders
Gupta, R., Ambasta, R. K., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117278 · Cited by 74
Mukherjee, P. K., Pradhan, A., Shah, F., Tekwani, B. L., & Avery, M. A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.005 · Cited by 74
Class I histone deacetylases catalyze lysine lactylation
Gonzatti, M. B., Hintzen, J. C. J., Sharma, I., Najar, M. A., Tsusaka, T., Marcinkiewicz, M. M., Crispim, C. V., Snyder, N. W., Burslem, G. M., & Goldberg, E. L. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110602 · Cited by 74
Babu, T., Sarkar, A., Karmakar, S., Schmidt, C., & Gibson, D. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c00445 · Cited by 74
Ma, C., Taghour, M. S., Belal, A., Mehany, A. B. M., Mostafa, N., Nabeeh, A., Eissa, I. H., & Al-Karmalawy, A. A. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.725135 · Cited by 74
Hernick, M., Gennadios, H. A., Whittington, D. A., Rusche, K. M., Christianson, D. W., & Fierke, C. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413560200 · Cited by 73
Histone modifications as a platform for cancer therapy
Espino, P. S., Drobic, B., Dunn, K. L., & Davie, J. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20387 · Cited by 73
Innovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
DNA and the chromosome – varied targets for chemotherapy
Nelson, S. M., Ferguson, L. R., & Denny, W. A. (2004) · Cell & Chromosome · doi:10.1186/1475-9268-3-2 · Cited by 72
3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition
Patil, V., Sodji, Q. H., Kornacki, J. R., Mrksich, M., & Oyelere, A. K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301769u · Cited by 72
Psammaplin A is a natural prodrug that inhibits class I histone deacetylase
Kim, D. H., Shin, J., & Kwon, H. J. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.6 · Cited by 72
Kobayashi, M., Mikami, D., Uwada, J., Yazawa, T., Kamiyama, K., Kimura, H., Taniguchi, T., & Iwano, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25809 · Cited by 72
Natural Products Impacting DNA Methyltransferases and Histone Deacetylases
Akoné, S. H., Ntie‐Kang, F., Stuhldreier, F., Ewonkem, M. B., Noah, A. M., Mouelle, S. E. M., & Müller, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00992 · Cited by 72
The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age
McLaughlin, F., Finn, P. W., & Thangue, N. B. L. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02792-2 · Cited by 72
Wittich, S., Scherf, H. R., Xie, C., Brosch, G., Loidl, P., Gerhäuser, C., & Jung, M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0208119 · Cited by 72
Shiozawa, K., Nakanishi, T., Tan, M., Fang, H.-B., Wang, W.-C., Edelman, M. J., Carlton, D., Gojo, I., Sausville, E. A., & Ross, D. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1587 · Cited by 72
Rajak, H., Singh, A. J., Raghuwanshi, K. K., Kumar, R., Dewangan, P. K., Veerasamy, R., Sharma, P. C., Dixit, A., & Mishra, P. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990191 · Cited by 71
Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8
Porter, N. J., & Christianson, D. W. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00330 · Cited by 71
Small Molecule Control of Chromatin Remodeling
Finley, A., & Copeland, R. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.024 · Cited by 71
Crabb, S. J., Howell, M., Rogers, H., Ishfaq, M., Yurek‐George, A., Carey, K. L., Pickering, B. M., East, P., Mitter, R., Maeda, S., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.004 · Cited by 71
Differential protein acetylation induced by novel histone deacetylase inhibitors
Glaser, K. B., Li, J., Pease, L. J., Staver, M. J., Marcotte, P. A., Guo, J., Frey, R. R., Garland, R. B., Heyman, H. R., Wada, C. K., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.082 · Cited by 71
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Ružić, D., Djoković, N., Srdić‐Rajić, T., Echeverría, C., Nikolic, K. M., & Santibanez, J. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010209 · Cited by 71
Krautkramer, K. A., Reiter, L., Denu, J. M., & Dowell, J. A. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00245 · Cited by 71
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
Kroesen, M., Büll, C., Gielen, P. R., Brok, I. C., Armandari, I., Wassink, M., Looman, M. W. G., Boon, L., den Brok, M. H., Hoogerbrugge, P. M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1164919 · Cited by 71
Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 70
Zinc Binding in HDAC Inhibitors: A DFT Study
Wang, D., Helquist, P., & Wiest, O. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo070739s · Cited by 70
Suzuki, T., Matsuura, A., Kouketsu, A., Nakagawa, H., & Miyata, N. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.074 · Cited by 70
The class I histone deacetylases of the platyhelminth parasite Schistosoma mansoni
Oger, F., Dubois, F., Caby, S., Noël, C., Cornette, J., Bertin, B., Capron, M., & Pierce, R. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.10.090 · Cited by 70
Design and synthesis of a novel class of histone deacetylase inhibitors
Lavoie, R., Bouchain, G., Fréchette, S., Woo, S. H., Khalil, E. A., Leit, S. M., Fournel, M., Yan, P. T., Trachy-Bourget, M.-C., Beaulieu, C., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00552-2 · Cited by 70
Dallavalle, S., Cincinelli, R., Nannei, R., Merlini, L., Morini, G., Penco, S., Pisano, C., Vesci, L., Barbarino, M., Zuco, V., et al. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.11.005 · Cited by 70
Tetracyclines inhibit activated B cell function
Kuzin, I. I., Snyder-Cappione, J. E., Ugine, G. D., Wu, D., Lee, S. M., Bushnell, T. P., Insel, R. A., Young, F. M., & Bottaro, A. (2001) · International Immunology · doi:10.1093/intimm/13.7.921 · Cited by 70
Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression
Yang, C., Huntoon, K. M., Ksendzovsky, A., Zhuang, Z., & Lonser, R. R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.007 · Cited by 70
JONES, P. G., Bottomley, M. J., Carfí, A., Cecchetti, O., Ferrigno, F., Surdo, P. L., Ontoria, J. M., Rowley, M., Scarpelli, R., Schultz‐Fademrecht, C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.02.026 · Cited by 69
Histone deacetylase activity is required for human oligodendrocyte progenitor differentiation
Conway, G. D., O'Bara, M. A., Vedia, B. H., Pol, S. U., & Sim, F. J. (2012) · Glia · doi:10.1002/glia.22410 · Cited by 69
New perspectives of valproic acid in clinical practice
Činčárová, L., Zdráhal, Z., & Fajkus, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.853037 · Cited by 69
Selective class IIa HDAC inhibitors: myth or reality
Giorgio, E. D., Gagliostro, E., & Brancolini, C. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1727-8 · Cited by 68
Metadata
- Authors
- Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Columbia University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Pavletich, Nikola P.
- Venue
- Nature
- Published
- 1999-09
- Volume
- 401
- Issue
- 6749
- Pages
- 188-193
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2135830745
- Cited by
- 1,714
- References
- 28
- Citations by year
- 2026: 39 · 2025: 48 · 2024: 40 · 2023: 55 · 2022: 28 · 2021: 66 · 2020: 62 · 2019: 50 · 2018: 52 · 2017: 70 · 2016: 68 · 2015: 74 · 2014: 67 · 2013: 78 · 2012: 82
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Genentech
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, trichostatin A, vorinostat, Aquifex aeolicus, crystal structure, catalytic site, zinc binding site, hyperthermophilic bacteria, anticancer agents, promyelocytic leukemia
- MeSH terms
- Vorinostat, Amino Acid Sequence, Enzyme Inhibitors, Escherichia coli, Histone Deacetylases, Humans, Hydroxamic Acids, Models, Molecular, Molecular Sequence Data, Protein Binding, Protein Conformation, Recombinant Fusion Proteins, Zinc, Gram-Negative Aerobic Rods and Cocci, Sequence Homology, Amino Acid, Crystallography, X-Ray, Catalytic Domain, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.